Australasia – the Pulmonary Fibrosis trial-ready destination
Why Australia and New Zealand?
Australasia’s clinical trials infrastructure, streamlined regulatory approval system along with available grants and incentives makes us a competitive clinical trials destination.
In relation to PF, we also have:
- A close-knit network of world-leading, experienced PF investigators united through PACT.
- A proven track record of outstanding recruitment to the world’s largest PF clinical trials.
- Unsurpassed network of Interstitial Lung Disease Multi-Disciplinary Meetings with standardised diagnostic algorithms.
- A receptive market for the development of genomics and precision medicine.
- A thriving research ecosystem.
- Australia’s Research and Development Tax Credit Scheme, click here.
- Australia’s clinical trial notification scheme streamlines early phase drug development, click here.
- Multi-site HREC/IRB approvals processes, find out more via NHMRC or Bellberry.